mr058666-web

Merck KGaA and Pfizer’s Bavencio fails at Phase 3 in gastric cancer

pharmafile | November 28, 2017 | News story | Research and Development |ย ย Bavencio, Cancer, Merck, Pfizer, pharmaย 

Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary endpoint in Phase 3 trials.

Bavencio (avelumab) proved unable to demonstrate superior rates of overall survival compared to standard chemotherapy as a third-line treatment for unresectable, recurrent or metastatic gastric cancer in patients whose cancer had returned or spread despite two prior rounds of treatment.

Despite the drugโ€™s failure, Chris Boshoff, Pfizerโ€™s Head of Immuno-oncology, maintained optimism at its prospects in the future, saying in a statement: โ€œWe are confident that our broad clinical development programme in both monotherapy and combinations across a range of cancers will continue to bring new potential treatment options to patients.โ€

Advertisement

Bavencio is already approved in skin and bladder cancer indications, securing authorisation earlier this year. The drug is expected to make the biggest waves in the lung cancer market, though data on its efficacy in this area are not expected until next year.

“Gastric cancer in the third-line setting is a particularly hard-to-treat and heterogeneous disease, and importantly, this was the first trial conducted with a checkpoint inhibitor compared to an active chemotherapy comparator rather than placebo in a global patient population,” remarked Luciano Rossetti, Global Head of R&D at Merck’s biopharma business.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

The Gateway to Local Adoption Series

Latest content